Results 141 to 150 of about 4,402,031 (267)
Critical Questions Surrounding the Shot-Blasting Treatment of Titanium Dental Implants. [PDF]
Gil J +8 more
europepmc +1 more source
Six critical questions for DNA repair enzymes in skincare products: a review in dialog. [PDF]
Yarosh DB, Rosenthal A, Moy R.
europepmc +1 more source
Visual Recovery Reflects Cortical MeCP2 Sensitivity in Rett Syndrome
ABSTRACT Objective Rett syndrome (RTT) is a devastating neurodevelopmental disorder with developmental regression affecting motor, sensory, and cognitive functions. Sensory disruptions contribute to the complex behavioral and cognitive difficulties and represent an important target for therapeutic interventions.
Alex Joseph Simon +12 more
wiley +1 more source
Real‐World Investigation of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disease
ABSTRACT Objective Satralizumab, a monoclonal antibody targeting the interleukin‐6 receptor, has demonstrated efficacy in clinical trials for neuromyelitis optica spectrum disorder (NMOSD). However, its real‐world effectiveness and safety compared to conventional immunosuppressive therapies remain uncertain.
Li‐Tsung Lin +2 more
wiley +1 more source
Assessing pain intensity: critical questions for researchers and clinicians. [PDF]
Jensen MP, Miró J, Euasobhon P.
europepmc +1 more source
Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference. [PDF]
Bast RC +42 more
europepmc +1 more source
ABSTRACT Objective This study aims to identify both fluid and neuroimaging biomarkers for CSF1R‐RD that can inform the optimal timing of treatment administration to maximize therapeutic benefit, while also providing sensitive quantitative measurements to monitor disease progression.
Tomasz Chmiela +13 more
wiley +1 more source
Transmission dynamics: critical questions and challenges. [PDF]
Antonovics J.
europepmc +1 more source
Inhibition of Classical and Alternative Complement Pathway by Ravulizumab and Eculizumab
ABSTRACT Objective To explore the feasibility of classical (CH50) and alternative (AH50) complement pathway activity as potential biomarkers for treatment guidance and monitoring during therapy with ravulizumab in patients with generalized myasthenia gravis (gMG) and compare these to therapeutic drug monitoring under eculizumab.
Lea Gerischer +14 more
wiley +1 more source

